Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...
If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 ...
Ascend Vitality is a U.S.-based telehealth provider offering physician-directed access to peptide therapy, metabolic support, and regenerative wellness treatments. The company partners with ...
Following the exercise in full of the Underwriters' Option, the total number of ADSs issued in the Offering will amount to 44,805,193, resulting in gross proceeds for the Company of approximately $172 ...
Smart sync: Data is securely transferred and displayed in Clue, alongside self-tracked symptoms and cycle information. Contextual insights: By combining wearable data with Clue tracking, members can ...
Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA 1 Phase 2a clinical trial for ontunisertib (AGMB-129), an ...
Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, ...
The Board of Directors and CEO Monica Manotas thank Tania Micki for her strong commitment and significant contributions to Tecan’s financial strategy, process optimization, and operational excellence ...
The share capital increase pertaining to the issuance of the in total 4,045,413 new shares in Tranche 1 and the Retail Offering has now been registered with the Norwegian Register of Business ...
TME Pharma will also discuss with other lenders who participated in the May and August 2025 bond issuance to try to procure similar extensions of their debt. TME Pharma believes now may be the right ...
From FY2026, focused restructuring, renewed R&D focus, and efficiency and digital initiatives will deliver near-term cost savings to enhance our path to profitability, including an expected minimum ...
Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback